270 related articles for article (PubMed ID: 21139642)
1. Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity.
Dowson C; Khan MS; Dasgupta P; Sahai A
Nat Rev Urol; 2010 Dec; 7(12):661-7. PubMed ID: 21139642
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
[TBL] [Abstract][Full Text] [Related]
3. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Discontinuation of Botulinum Toxin A Intradetrusor Injections for Neurogenic Detrusor Overactivity: A Multicenter Study.
Baron M; Peyronnet B; Aublé A; Hascoet J; Castel-Lacanal E; Miget G; Le Doze S; Prudhomme T; Manunta A; Cornu JN; Gamé X
J Urol; 2019 Apr; 201(4):769-776. PubMed ID: 30359679
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.
Abdel-Meguid TA
J Urol; 2010 Dec; 184(6):2423-8. PubMed ID: 20952003
[TBL] [Abstract][Full Text] [Related]
6. New therapeutic options for refractory neurogenic detrusor overactivity.
Giannantoni A; Mearini E; Di Stasi SM; Costantini E; Zucchi A; Mearini L; Fornetti P; Del Zingaro M; Navarra P; Porena M
Minerva Urol Nefrol; 2004 Mar; 56(1):79-87. PubMed ID: 15195033
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review.
Soljanik I
Drugs; 2013 Jul; 73(10):1055-66. PubMed ID: 23775527
[TBL] [Abstract][Full Text] [Related]
8. Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity.
Ghalayini IF; Al-Ghazo MA; Elnasser ZA
Int Urol Nephrol; 2009 Dec; 41(4):805-13. PubMed ID: 19184509
[TBL] [Abstract][Full Text] [Related]
9. Intravesical electromotive botulinum toxin type A administration--part II: Clinical application.
Kajbafzadeh AM; Ahmadi H; Montaser-Kouhsari L; Sharifi-Rad L; Nejat F; Bazargan-Hejazi S
Urology; 2011 Feb; 77(2):439-45. PubMed ID: 20800886
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin treatment for bladder dysfunction.
Santos-Silva A; da Silva CM; Cruz F
Int J Urol; 2013 Oct; 20(10):956-62. PubMed ID: 23634720
[TBL] [Abstract][Full Text] [Related]
11. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.
Linsenmeyer TA
J Spinal Cord Med; 2013 Sep; 36(5):402-19. PubMed ID: 23941788
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
Karsenty G; Denys P; Amarenco G; De Seze M; Gamé X; Haab F; Kerdraon J; Perrouin-Verbe B; Ruffion A; Saussine C; Soler JM; Schurch B; Chartier-Kastler E
Eur Urol; 2008 Feb; 53(2):275-87. PubMed ID: 17988791
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB).
Mohee A; Khan A; Harris N; Eardley I
BJU Int; 2013 Jan; 111(1):106-13. PubMed ID: 22672569
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis.
Khan S; Game X; Kalsi V; Gonzales G; Panicker J; Elneil S; Apostolidis A; Hamid R; Dasgupta P; Kessler TM; Fowler CJ
J Urol; 2011 Apr; 185(4):1344-9. PubMed ID: 21334639
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
[TBL] [Abstract][Full Text] [Related]
16. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
Al Edwan GM; Mansi HH; Atta ONM; Shaath MM; Al Adwan R; Mahafza W; Afram KM; Ababneh O; Al Adwan D; Muheilan MM
J Pediatr Surg; 2019 Mar; 54(3):595-599. PubMed ID: 29887168
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of electromotive drug administration in delivering botulinum toxin a in children with neuropathic detrusor overactivity-outcomes of a pilot study.
Koh C; Melling CV; Jennings C; Lewis M; Goyal A
J Pediatr Urol; 2019 Oct; 15(5):552.e1-552.e8. PubMed ID: 31326328
[TBL] [Abstract][Full Text] [Related]
18. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis.
Chen JL; Kuo HC
Investig Clin Urol; 2020 Feb; 61(Suppl 1):S33-S42. PubMed ID: 32055752
[TBL] [Abstract][Full Text] [Related]
19. Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity.
Kaviani A; Khavari R
Urol Clin North Am; 2017 Aug; 44(3):463-474. PubMed ID: 28716326
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders.
Lin YH; Chiang BJ; Liao CH
Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
